BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide

... | May 6, 2023

Related Keywords

United States ,Beijing ,China ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Chinese ,Ma Jun ,Lai Wang ,Exchange Commission ,Harbin Institute Of Hematology Oncology ,Supervisor Of Supervisory Committee ,American Cancer Society ,End Results Program ,Chinese Society Of Clinical Oncology ,China National Medical Products Administration ,National Cancer Institute ,Lymphoma Research Foundation ,Supplemental New Drug Applications ,Supplemental Applications ,Gene Beigene Receives New Approvals ,Business Wire ,Global Head ,Healthy China ,Professor Ma Jun ,Harbin Institute ,Chief Supervisor ,Supervisory Committee ,Chinese Society ,Chronic Lymphocytic Leukemia ,Small Lymphocytic Lymphoma ,Private Securities Litigation Reform Act ,Chronic Lymphocytic ,Small Lymphocytic ,National Cancer ,End Results ,Cancer Stat Facts ,Accessed October ,Graw Hill Education ,American Cancer ,Updated May ,Lymphoma Research ,Accessed December ,Cancer Journal ,Beigene ,Td Stock Exchange ,News ,Information ,Press Release ,Brukinsa ,Us ,Approved ,Or ,Treatment ,End ,M ,N ,Gas ,Multiple ,Indications ,More ,Han ,5 ,Arkets Bgne Us07725l1026 ,